Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1890 1
1894 1
1900 1
1909 1
1949 1
1952 1
1954 1
1961 1
1970 1
1972 2
1974 1
1975 7
1976 6
1977 9
1978 9
1979 6
1980 11
1981 25
1982 26
1983 19
1984 17
1985 25
1986 33
1987 28
1988 28
1989 42
1990 41
1991 40
1992 43
1993 40
1994 37
1995 53
1996 45
1997 45
1998 39
1999 54
2000 63
2001 55
2002 72
2003 71
2004 65
2005 82
2006 78
2007 100
2008 96
2009 81
2010 99
2011 81
2012 77
2013 83
2014 98
2015 99
2016 94
2017 71
2018 80
2019 92
2020 99
2021 85
2022 80
2023 85
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

2,547 results

Results by year

Filters applied: . Clear all
Page 1
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. Among authors: dent g. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.
OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease. ...A dose- …
OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN: EMERGE and ENGAGE were two rando …
Management of frailty: opportunities, challenges, and future directions.
Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Dent E, et al. Lancet. 2019 Oct 12;394(10206):1376-1386. doi: 10.1016/S0140-6736(19)31785-4. Lancet. 2019. PMID: 31609229 Review.
We advocate change towards individually tailored interventions that preserve an individual's independence, physical function, and cognition. This change can be addressed by promoting the recognition of frailty, furthering advancements in evidence-based treatment options, a …
We advocate change towards individually tailored interventions that preserve an individual's independence, physical function, and cog …
Frailty measurement in research and clinical practice: A review.
Dent E, Kowal P, Hoogendijk EO. Dent E, et al. Eur J Intern Med. 2016 Jun;31:3-10. doi: 10.1016/j.ejim.2016.03.007. Epub 2016 Mar 31. Eur J Intern Med. 2016. PMID: 27039014 Review.
Frailty occurs when multiple physiological systems decline, to the extent that an individual's cellular repair mechanisms cannot maintain system homeostasis. This review gives an overview of the definitions and measurement of frailty in research and clinical practice, incl …
Frailty occurs when multiple physiological systems decline, to the extent that an individual's cellular repair mechanisms cannot main …
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Satoh T, Wang L, Espinosa-Diez C, Wang B, Hahn SA, Noda K, Rochon ER, Dent MR, Levine AR, Baust JJ, Wyman S, Wu YL, Triantafyllou GA, Tang Y, Reynolds M, Shiva S, Hilaire CS, Gomez D, Goncharov DA, Goncharova EA, Chan SY, Straub AC, Lai YC, McTiernan CF, Gladwin MT. Satoh T, et al. Among authors: dent mr. Circulation. 2021 Aug 24;144(8):615-637. doi: 10.1161/CIRCULATIONAHA.121.053889. Epub 2021 Jun 23. Circulation. 2021. PMID: 34157861 Free PMC article.
Barrett's oesophagus.
Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Dent J, et al. J Gastroenterol Hepatol. 1991 Jan-Feb;6(1):1-22. doi: 10.1111/j.1440-1746.1991.tb01137.x. J Gastroenterol Hepatol. 1991. PMID: 1883971 Review. No abstract available.
Thiol-catalyzed formation of NO-ferroheme regulates intravascular NO signaling.
DeMartino AW, Poudel L, Dent MR, Chen X, Xu Q, Gladwin BS, Tejero J, Basu S, Alipour E, Jiang Y, Rose JJ, Gladwin MT, Kim-Shapiro DB. DeMartino AW, et al. Among authors: dent mr. Nat Chem Biol. 2023 Oct;19(10):1256-1266. doi: 10.1038/s41589-023-01413-3. Epub 2023 Sep 14. Nat Chem Biol. 2023. PMID: 37710075 Free PMC article.
Autophagy: cancer's friend or foe?
Bhutia SK, Mukhopadhyay S, Sinha N, Das DN, Panda PK, Patra SK, Maiti TK, Mandal M, Dent P, Wang XY, Das SK, Sarkar D, Fisher PB. Bhutia SK, et al. Among authors: dent p. Adv Cancer Res. 2013;118:61-95. doi: 10.1016/B978-0-12-407173-5.00003-0. Adv Cancer Res. 2013. PMID: 23768510 Free PMC article. Review.
Sarcopenia measurement in research and clinical practice.
Dent E, Woo J, Scott D, Hoogendijk EO. Dent E, et al. Eur J Intern Med. 2021 Aug;90:1-9. doi: 10.1016/j.ejim.2021.06.003. Epub 2021 Jul 6. Eur J Intern Med. 2021. PMID: 34238636 Review.
Sarcopenia is a disease related to accelerated loss of skeletal muscle and subsequent decline in functional capacity. It affects approximately 13% of the world's population aged over 60 years. Sarcopenia is primarily managed and prevented through a combination of exercise …
Sarcopenia is a disease related to accelerated loss of skeletal muscle and subsequent decline in functional capacity. It affects approximate …
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C, Tian Y, Aisen PS, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S. Mallinckrodt C, et al. Among authors: dent g. J Prev Alzheimers Dis. 2023;10(2):171-177. doi: 10.14283/jpad.2023.6. J Prev Alzheimers Dis. 2023. PMID: 36946443 Clinical Trial.
OBJECTIVES: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer's disease (AD) have been published. In EMERGE, but not in ENGAGE, high-dose aducanumab demonstrated significant treatment effects …
OBJECTIVES: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzhei …
MDA-7/IL-24: multifunctional cancer killing cytokine.
Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S, Dent P, Wang XY, Sarkar D, Fisher PB. Menezes ME, et al. Among authors: dent p. Adv Exp Med Biol. 2014;818:127-53. doi: 10.1007/978-1-4471-6458-6_6. Adv Exp Med Biol. 2014. PMID: 25001534 Free PMC article. Review.
2,547 results